诊断学理论与实践

诊断学理论与实践 >

2020 , Vol. 19 >Issue 05: 460 - 468

DOI: https://doi.org/10.16150/j.1671-2870.2020.05.004

指南与共识

帕金森病血压管理专家共识

展开
  • 1.上海交通大学医学院附属瑞金医院 a. 神经内科;b. 上海市高血压研究所,上海 200025
    2.河北州中西医结合医院神经内科,河北 沧州 061001
    3.佛山市第一人民医院神经内科,广东 佛山 528000
    4.中国医学科学院北京协和医院神经内科,北京 100730
    5.上海交通大学医学院附属同仁医院神经内科,上海 200050
    6.安徽医科大学第一附属医院神经内科,安徽 合肥 230022
    7.中山大学附属第一医院神经内科,广东 广州 510080
    8.安徽中医药大学神经病学研究所,安徽 合肥 230061
    9.蚌埠医学院第一附属医院神经内科,安徽 蚌埠 233030
    10.加拿大多伦多大学医学院西区医院运动障碍疾病中心,多伦多 M5T 2S8

收稿日期: 2020-02-28

  网络出版日期: 2022-07-14

收起

本文引用格式

陈施吾, 窦荣花, 王玉凯, 王含, 王晓平, 陈先文, 陈玲, 王训, 屈洪党, 陈生弟, Susan Fox, 李燕, 王刚 . 帕金森病血压管理专家共识[J]. 诊断学理论与实践, 2020 , 19(05) : 460 -468 . DOI: 10.16150/j.1671-2870.2020.05.004

参考文献

[1] Klanbut S, Phattanarudee S, Wongwiwatthananukit S, et al. Symptomatic orthostatic hypotension in Parkinson’s disease patients: prevalence, associated factors and its impact on balance confidence[J]. J Neurol Sci, 2018, 385: 168-174.
[2] Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s disease and related synucleinopathies: prioritisation of treatment targets[J]. Lancet Neurol, 2016, 15(9): 954-966.
[3] Allcock LM, Ullyart K, Kenny RA, et al. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 2004, 75(10): 1470-1471.
[4] Senard JM, Raï S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 1997, 63(5): 584-589.
[5] Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment[J]. J Am Coll Cardiol, 2015, 66(7): 848-860.
[6] Palma JA, Kaufmann H. Orthostatic hypotension in Parkinson disease[J]. Clin Geriatr Med, 2020, 36(1): 53-67.
[7] Umehara T, Matsuno H, Toyoda C, et al. Clinical characteristics of supine hypertension in de novo Parkinson di-sease[J]. Clin Auton Res, 2016, 26(1): 15-21.
[8] Tadic M, Cuspidi C, Pencic-Popovic B, et al. The influe-nce of night-time hypertension on left ventricular mechanics[J]. Int J Cardiol, 2017, 243: 443-448.
[9] Di Stefano C, Sobrero G, Milazzo V, et al. Cardiac organ damage in patients with Parkinson’s disease and reverse dipping[J]. J Hypertens, 2020, 38(2): 289-294.
[10] Chatzistamatiou EI, Moustakas GN, Veioglanis S, et al. Nocturnal hypertension: poor correlation with office blood pressure but strong prognostic factor for target organ damage[J]. Hellenic J Cardiol, 2012, 53(4): 263-272.
[11] Baker J, Kimpinski K. Management of supine hypertension complicating neurogenic orthostatic hypotension[J]. CNS Drugs, 2017, 31(8): 653-663.
[12] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension[J]. J Hypertens, 2018, 36(10): 1953-2041.
[13] 王刚, 崔海伦. 帕金森病临床诊断和治疗现状及进展[J]. 重庆医科大学学报, 2019, 44(4): 86-89.
[14] 中国高血压防治指南修订委员会, 高血压联盟(中国)中华医学会心血管病学分会, 中国医师协会高血压专业委员会, 中国医疗保健国际交流促进会高血压分会, 中国老年医学学会高血压分会. 中国高血压防治指南(2018年修订版)[J]. 心脑血管病防治, 19(1): 1-44.
[15] 中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第三版)[J]. 药学与临床研究, 2014, 27(4): 428-433.
[16] Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome[J]. Auton Neurosci, 2011, 161(1-2): 46-48.
[17] Rutan GH, Hermanson B, Bild DE, et al. Orthostatic hypotension in older adults[J]. Hypertension, 1992, 19(6 Pt 1): 508-519.
[18] Velseboer DC, De Haah RJ, Wieling W, et al. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis[J]. Parkinsonism Relat Disord, 2011, 17(10): 724-729.
[19] Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go?[J]. Mov Disord, 2015, 30(5): 639-645.
[20] Kaufmann H, Palma JA. Neurogenic orthostatic hypotension: the very basics[J]. Clin Auton Res, 2017, 27 Suppl 1: 39-43.
[21] Krediet CT, Van Lieshout JJ, Bogert LW, et al. Leg crossing improves orthostatic tolerance in healthy subjects: a placebo-controlled crossover study[J]. Am J Physiol Heart Circ Physiol, 2006, 291(4): H1768-H1772.
[22] Goldstein DS, Cheshire WP. Beat-to-beat blood pressure and heart rate responses to the valsalva maneuver[J]. Clin Auton Res, 2017, 27(6): 361-367.
[23] Diedrich A, Biaggioni I. Segmental orthostatic fluid shifts[J]. Clin Auton Res, 2004, 14(3): 146-147.
[24] Schdreglmann SR, Büchele F, Sommerauer M, et al. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson’s disease[J]. Eur J Neurol, 2017, 24(4): 545-551.
[25] Hoehn MM. Levodopa-induced postural hypotension. Treatment with fludrocortisone[J]. Arch Neurol, 1975, 32(1): 50-51.
[26] Sandroni P, Benarroch EE, Wijdicks EF. Caudate hemorrhage as a possible complication of midodrine-induced supine hypertension[J]. Mayo Clin Proc, 2001, 76(12): 1275.
[27] Kaufmann H, Brannan T, Krakoff L, et al. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine)[J]. Neurology, 1988, 38(6): 951-956.
[28] Byun JI, Moon J, Kim DY, et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension[J]. Neurology, 2017, 89(10): 1078-1086.
[29] Coll M, Rodriguez S, Raurell I, et al. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats[J]. Hepatology, 2012, 56(5): 1849-1860.
[30] Hauser RA, Biaggioni I, Hewitt LA, et al. Integrated analysis of droxidopa for the treatment of neurogenic orthostatic hypotension in patients with Parkinson disease[J]. Mov Disord Clin Pract, 2018, 5(6): 627-634.
[31] Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure[J]. Hypertension, 2014, 64(6): 1235-1240.
[32] Okamoto LE, Shibao CA, Gamboa A, et al. Synergistic pressor effect of atomoxetine and pyridostigmine in patients with neurogenic orthostatic hypotension[J]. Hypertension, 2019, 73(1): 1235-1241.
[33] 金兆清, 薛越, 刘长林, 等. 中药升压汤治疗慢性低血压病效果观察[J]. 解放军预防医学杂志, 2010, 28(1): 78.
[34] Grijalva CG, Biaggioni I, Griffin MR, et al. Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension[J]. J Am Heart Assoc, 2017, 6(10): e006848.
[35] Smith W, Wan H, Much D, et al. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study[J]. Clin Auton Res, 2016, 26(4): 269-277.
[36] Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B)[J]. Mov Disord, 2015, 30(5): 646-654.
[37] Pérez-Lloret S, Quarracino C, Otero-Losada M, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial[J]. Expert Opin Pharmacother, 2019, 20(6): 635-645.
[38] Hale GM, Brenner M. Atomoxetine for orthostatic hypotension in an elderly patient over 10 weeks: a case report[J]. Pharmacotherapy, 2015, 35(9): e141-e148.
[39] Jordan J, Tank J, Heusser K, et al. What do we really know about supine hypertension in patients with orthostatic hypotension[J]. Curr Opin Cardiol, 2019, 34(4): 384-389.
[40] Goldstein DS, Pechnik S, Holmes C, et al. Association between supine hypertension and orthostatic hypotension in autonomic failure[J]. Hypertension, 2003, 42(2): 136-142.
[41] Biaggioni I, Robertson RM. Hypertension in orthostatic hypotension and autonomic dysfunction[J]. Cardiol Clin, 2002, 20(2): 291-301.
[42] Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease[J]. J Neurol Sci, 2011, 310(1-2): 123-128.
[43] Pathak A, Senard JM. Blood pressure disorders during Parkinson’s disease: epidemiology, pathophysiology and management[J]. Expert Rev Neurother, 2006, 6(8): 1173-1180.
[44] 李华, 李锐洁. 老年人体位性低血压合并卧位高血压[J]. 中华高血压杂志, 2007, 15(4): 346-349.
[45] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 血管紧张素转换酶抑制剂在心血管病中应用中国专家共识[J]. 中华心血管病杂志, 2007, 35(2): 97-106.
[46] Kooner JS, Raimbach S, Bannister R, et al. Angiotensin converting enzyme inhibition lowers blood pressure in patients with primary autonomic failure independently of plasma renin levels and sympathetic nervous activity[J]. J Hypertens Suppl, 1989, 7(6): S42-S43.
[47] Arnold AC, Okamoto LE, Gamboa A, et al. Angiotensin Ⅱ, independent of plasma renin activity, contributes to the hypertension of autonomic failure[J]. Hypertension, 2013, 61(3): 701-706.
[48] Okamoto LE, Gamboa A, Shibao CA, et al. Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension[J]. Hypertension, 2014, 64(6): 1241-1247.
[49] Shibao CA, Kaufmann H. Pharmacotherapy of cardiovascular autonomic dysfunction in Parkinson disease[J]. CNS Drugs, 2017, 31(11): 975-989.
[50] Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies[J]. Mov Disord, 2018, 33(3): 372-390.
[51] Jordan J, Shannon JR, Pohar B, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure[J]. J Am Soc Nephrol, 1999, 10(1): 35-42.
[52] Luciano GL, Brennan MJ, Rothberg MB. Postprandial hypotension[J]. Am J Med, 2010, 123(3): 281.
[53] Pavelic A, Krbot Skoric M, Crnošija L, et al. Postprandial hypotension in neurological disorders: systematic review and meta-analysis[J]. Clin Auton Res, 2017, 27(4): 263-271.
[54] Uumhara T, Nnakahara A, Matsuno H, et al. Predictors of postprandial hypotension in elderly patients with de novo Parkinson’s disease[J]. J Neural Transm (Vienna), 2016, 123(11): 1331-1339.
[55] Jansen RW, Peeters TL, Lenders JW, et al. Somatostatin analog octreotide (SMS 201-995) prevents the decrease in blood pressure after oral glucose loading in the elderly[J]. J Clin Endocrinol Metab, 1989, 68(4): 752-756.
[56] Hoeldtke RD, O’Dorisio TM, Boden G. Treatment of autonomic neuropathy with a somatostatin analogue SMS-201-995[J]. Lancet, 1986, 2(8507): 602-605.
[57] Shibao C, Gamboa A, Diedrich A, et al. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure[J]. Hypertension, 2007, 50(1): 54-61.
[58] Jian ZJ, Zhou BY. Efficacy and safety of acarbose in the treatment of elderly patients with postprandial hypotension[J]. Chin Med J (Engl), 2008, 121(20): 2054-2059.
[59] Maruta T, Komai K, Takamori M, et al. Voglibose inhibits postprandial hypotension in neurologic disorders and elderly people[J]. Neurology, 2006, 66(9): 1432-1434.
[60] Noack C, Schroeder C, Heusser K, et al. Cardiovascular effects of levodopa in Parkinson’s disease[J]. Parkinsoni-sm Relat Disord, 2014, 20(8): 815-818.
[61] Wilson JA, Smith RG. The prevalence and aetiology of long-term L-dopa side-effects in elderly Parkinsonian patients[J]. Age Ageing, 1989, 18(1): 11-16.
[62] Churchyard A, Mathias CJ, Lees AJ. Selegiline-induced postural hypotension in Parkinson’s disease: a longitudinal study on the effects of drug withdrawal[J]. Mov Disord, 1999, 14(2): 246-251.
[63] Corder CN, Kanefsky TM, McDonald RH Jr, et al. Postural hypotension: adrenergic responsivity and levodopa therapy[J]. Neurology, 1977, 27(10): 921-927.
[64] Lokhandwala MF, Barrett RJ. Dopamine receptor agonist in cardiovascular therapy[J]. Drug Dev Res, 3(4): 299-310.
[65] 温洪波, 张振馨, 罗毅, 等. 普拉克索治疗帕金森病的多中心、随机、双盲、溴隐亭对照临床疗效和安全性研究[J]. 中华神经科杂志, 2006, 39(9): 604-608.
[66] Montastruc JL, Chaumerliac C, Desboeuf K, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database[J]. Clin Neuropharmacol, 2000, 23(5): 271-275.
[67] Bhattacharya KF, Nouri S, Olanow CW, et al. Selegiline in the treatment of Parkinson’s disease: its impact on orthostatic hypotension[J]. Parkinsonism Relat Disord, 2003, 9(4): 221-224.
[68] Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease[J]. Drugs, 2000, 59(6): 1233-1250.
[69] Teychenne PF, Calne DB, Lewis PJ, et al. Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase[J]. Clin Pharmacol Ther, 1975, 18(3): 273-277.
[70] Rose LM, Ohlinger MJ, Mauro VF. A hypertensive reaction induced by concurrent use of selegiline and dopamine[J]. Ann Pharmacother, 2000, 34(9): 1020-1024.
Options
文章导航

/

〈 〉